Related Experiment Videos
NCL-6-124I: a PET agent for the adrenal
C W Somawardhana1, J K Amartey, M Kojima
1Radionuclide and Cytclotron Operations Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.
International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes
|January 1, 1990
Summary
The novel radiopharmaceutical 6 beta-[124I]iodomethyl-19-nor-cholest-5(10)-en-3 beta-ol (NCL-6-124I) was synthesized. It demonstrated greater stability in chloroform compared to refrigerated injectable solutions, suggesting improved storage potential.
Area of Science:
- Radiopharmaceutical Chemistry
- Nuclear Medicine
- Organic Synthesis
Background:
- Radiopharmaceuticals are crucial for diagnostic imaging and therapy.
- Stability of radiopharmaceuticals during storage is critical for their effective use.
- Autoradiolytic decomposition can limit the shelf-life and efficacy of radiotracers.
Purpose of the Study:
- To synthesize the novel radiopharmaceutical 6 beta-[124I]iodomethyl-19-nor-cholest-5(10)-en-3 beta-ol (NCL-6-124I).
- To evaluate the stability of NCL-6-124I against autoradiolytic decomposition under different storage conditions.
Main Methods:
- Synthesis of 6 beta-[124I]iodomethyl-19-nor-cholest-5(10)-en-3 beta-ol (NCL-6-124I) using established radiolabeling techniques.
- Assessment of radiopharmaceutical stability by monitoring decomposition in chloroform and as an injectable solution at 5 degrees C.
Main Results:
- Successful synthesis of the target radiopharmaceutical NCL-6-124I.
- NCL-6-124I exhibited reduced autoradiolytic decomposition when stored in chloroform.
- Injectable solutions of NCL-6-124I showed greater decomposition at 5 degrees C compared to storage in chloroform.
Conclusions:
- The synthesized radiopharmaceutical NCL-6-124I demonstrates enhanced stability in chloroform.
- This finding suggests that chloroform may be a suitable solvent for improved storage of NCL-6-124I.
- Further studies are warranted to explore the full implications for radiopharmaceutical shelf-life and clinical application.